News
WGS
82.25
+0.62%
0.51
GeneDx Holdings (WGS) Is Up 14.8% After Loss-Making Q2, New Capital Raise And Guidance Reaffirmation
Simply Wall St · 1d ago
GeneDx launches new online offering to expand accessibility of exome testing
TipRanks · 1d ago
GeneDx (WGS) Q2 2026 Earnings Call Transcript
The Motley Fool · 1d ago
Cathie Wood loads up SpaceX, AI infra names, continues trimming Roblox, Palantir
Seeking Alpha · 2d ago
Weekly Report: what happened at WGS last week (0803-0807)?
Weekly Report · 2d ago
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 6d ago
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Seeking Alpha · 6d ago
Cathie Wood’s ARK buys $23M SpaceX, $17M Nvidia; offloads Roblox, Palantir
Seeking Alpha · 6d ago
Mid-cap Sell streak: Stocks trapped longest in bearish Quant ratings
Seeking Alpha · 08/05 15:12
Cathie Wood Cashes In on Palantir’s Post-Earnings Surge
TipRanks · 08/05 11:31
GeneDx Holdings Corp. Earnings Call Highlights Risks
TipRanks · 08/05 00:45
GeneDx (WGS) Stock Climbs On Strong Margins As Reimbursement Lags
Simply Wall St · 08/04 22:28
Analysts Offer Insights on Healthcare Companies: Design Therapeutics (DSGN), Certara (CERT) and GeneDx Holdings (WGS)
TipRanks · 08/04 14:40
GeneDx Earns Buy Rating as Massaro Sees High‑Margin Exome Growth Driving Profitability, Sets $90 Price Target
TipRanks · 08/04 13:44
Kyle Mikson Boosts GeneDx Price Target to $90 and Reaffirms Buy Rating on Strengthened Financial Outlook
TipRanks · 08/04 13:37
Piper Sandler Sticks to Its Buy Rating for GeneDx Holdings (WGS)
TipRanks · 08/04 13:28
GeneDx Holdings Is Maintained at Buy by Canaccord Genuity
Dow Jones · 08/04 12:31
GeneDx Holdings Price Target Raised to $90.00/Share From $75.00 by Canaccord Genuity
Dow Jones · 08/04 12:31
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90
Benzinga · 08/04 12:21
At a glance: stocks gapping up premarket
Seeking Alpha · 08/04 11:10
More
Webull provides a variety of real-time WGS stock news. You can receive the latest news about GeneDx Holdings Corp through multiple platforms. This information may help you make smarter investment decisions.
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.